2021
The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNarcotic AntagonistsOpioid-Related DisordersReceptors, Opioid, muSubstance Withdrawal SyndromeConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trials
1991
Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes
Sofuoglu M, Portoghese P, Takemori A. Cross-tolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes. Life Sciences 1991, 49: pl153-pl156. PMID: 1658509, DOI: 10.1016/0024-3205(91)90397-t.Peer-Reviewed Original ResearchConceptsDelta opioid receptor subtypesOpioid receptor subtypesAntinociceptive effectReceptor subtypesAntinociceptive ED50 valueDelta-opioid receptor-selective peptideCross-tolerance studiesReceptor-selective peptideSpinal cordTolerance developmentFurther evidenceDPDPEED50 valuesMiceDADLEDAMGOSignificant increaseDSLETSame pretreatmentSubtypesAdministrationSelective peptidesCordFNA